- Amarin (NASDAQ:AMRN): Q1 Non-GAAP EPS of $0.03 beats by $0.07; GAAP EPS of $0.00 beats by $0.05.
- Revenue of $142.17M (-8.3% Y/Y) misses by $4.93M.
- “Results in the first quarter of 2021 reflect a mixture of positive accomplishments and continued headwinds, particularly from COVID-19, the effects of which continued to be more persistent than was hoped,” stated John Thero, president and chief executive officer of Amarin. “A clear highlight of the quarter was the broad label for VAZKEPA which is now authorized for marketing in Europe. The opportunity for VAZKEPA in Europe is large and our team in Europe is making tremendous progress.”
- Press Release